Care Dx, Inc. CDNA
We take great care to ensure that the data presented and summarized in this overview for CareDx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDNA
View all-
Black Rock Inc. New York, NY5.29MShares$109 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.54MShares$93.5 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.15MShares$64.8 Million1.65% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2.99MShares$61.6 Million0.89% of portfolio
-
State Street Corp Boston, MA2.04MShares$42 Million0.0% of portfolio
-
Bamco Inc New York, NY1.88MShares$38.7 Million0.16% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.1.65MShares$34.1 Million0.04% of portfolio
-
Nikko Asset Management Americas, Inc.1.65MShares$34.1 Million0.6% of portfolio
-
Fred Alger Management, LLC New York, NY1.5MShares$31 Million0.24% of portfolio
-
Invesco Ltd. Atlanta, GA1.46MShares$30.2 Million0.01% of portfolio
Latest Institutional Activity in CDNA
Top Purchases
Top Sells
About CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Insider Transactions at CDNA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 04
2024
|
Jeffrey Adam Novack Secretary and General Counsel |
SELL
Open market or private sale
|
Direct |
1,917
-1.71%
|
$49,842
$26.0 P/Share
|
Nov 26
2024
|
Peter Maag |
SELL
Open market or private sale
|
Direct |
5,000
-1.49%
|
$125,000
$25.0 P/Share
|
Nov 26
2024
|
Peter Maag |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.47%
|
$60,000
$12.24 P/Share
|
Nov 25
2024
|
Jeffrey Adam Novack Secretary and General Counsel |
SELL
Open market or private sale
|
Direct |
1,223
-0.54%
|
$29,352
$24.0 P/Share
|
Nov 18
2024
|
Jeffrey Adam Novack Secretary and General Counsel |
SELL
Open market or private sale
|
Direct |
5,534
-1.57%
|
$116,214
$21.88 P/Share
|
Nov 06
2024
|
Jeffrey Adam Novack Secretary and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
452
-0.38%
|
$10,396
$23.21 P/Share
|
Nov 01
2024
|
George Bickerstaff |
BUY
Exercise of conversion of derivative security
|
Direct |
7,481
+2.97%
|
$37,405
$5.67 P/Share
|
Nov 01
2024
|
Abhishek Jain Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,371
-2.7%
|
$162,162
$22.64 P/Share
|
Nov 01
2024
|
Jeffrey Adam Novack Secretary and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,905
-1.57%
|
$41,910
$22.64 P/Share
|
Oct 04
2024
|
Michael Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
837
+0.6%
|
-
|
Sep 12
2024
|
Keith Kennedy Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,101
+50.0%
|
-
|
Sep 12
2024
|
Jessica Meng Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,576
+50.0%
|
-
|
Sep 09
2024
|
Abhishek Jain Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,807
-1.02%
|
$75,789
$27.43 P/Share
|
Sep 06
2024
|
Abhishek Jain Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
697
-0.25%
|
$18,819
$27.1 P/Share
|
Aug 21
2024
|
Alexander L Johnson Officer |
SELL
Open market or private sale
|
Direct |
21,557
-7.03%
|
$689,824
$32.58 P/Share
|
Aug 21
2024
|
Alexander L Johnson Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,557
+6.57%
|
$495,811
$23.48 P/Share
|
Aug 20
2024
|
Alexander L Johnson Officer |
SELL
Open market or private sale
|
Direct |
39,466
-12.16%
|
$1,302,378
$33.17 P/Share
|
Aug 20
2024
|
Alexander L Johnson Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,466
+10.84%
|
$907,718
$23.48 P/Share
|
Aug 20
2024
|
Peter Maag |
SELL
Open market or private sale
|
Direct |
35,552
-3.35%
|
$1,173,216
$33.05 P/Share
|
Aug 20
2024
|
Peter Maag |
BUY
Exercise of conversion of derivative security
|
Direct |
26,708
+6.81%
|
$186,956
$7.96 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 259K shares |
---|---|
Exercise of conversion of derivative security | 119K shares |
Open market or private sale | 144K shares |
---|---|
Payment of exercise price or tax liability | 92.6K shares |